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IMPLANTABLE CONTROLLED RELEASE 
DEVICE TO DELIVER DRUGS DIRECTLY 
TO AN INTERNAL PORTION OF THE BODY 
This application is a Continuation-in-Part of application 
Ser. No. 08/534,854 ?led Sep. 27, 1995 noW U.S. Pat. No. 
5,773,019. 
TECHNICAL FIELD 
The present invention relates to a simple and implantable 
sustained release drug delivery device With an inner core 
containing an effective amount of a loW solubility agent 
covered by a non-bioerodible polymer coating layer that is 
permeable to the loW solubility agent. Also, the polymer 
coating layer holds the drug in the correct anatomic position 
and essentially prevents disintegration of the drug core While 
not signi?cantly impairing the drug release rate. A method 
for treating a mammal to obtain a desired local or systemic 
physiological or pharmacological effect by surgically 
implanting the device into a mammal in need of treatment is 
also disclosed. 
BACKGROUND 
Uveitis is a disease of the eye Which can be located 
throughout the eye including the posterior and anterior 
chambers of the eye as Well as the vitreous body. Uveitis, the 
in?ammation of the uvea, is responsible for about 10% of 
the visual impairment in the United States. 
Panuveitis refers to in?ammation of the entire uveal 
(vascular) layer of the eye. Posterior uveitis generally refers 
to chorioretinitis and anterior uveitis refers to iridocyclitis. 
The in?ammatory products, that is, cells, ?brin, excess 
protein, of these in?ammations are commonly found in the 
?uid spaces of the eye including the anterior chamber, 
posterior chamber and vitreous space as Well as the tissue 
involved in the in?ammatory response. Uveitis may occur 
folloWing surgical or traumatic injury to the eye, as a 
component of an autoimmune disorder such as rheumatoid 
arthritis, Behcet’s disease, ankylosing spondylitis, 
sarcoidosis, as an isolated immune mediated ocular disorder, 
i.e., pars planitis, iridodyclitis etc., unassociated With knoWn 
etiologies, and folloWing certain systemic diseases Which 
cause antibody-antigen complexes to be deposited in uveal 
tissues. Together these disorders represent non-infectious 
uveitities. 
Cyclosporine A, a 1.2 kd cyclic peptide Which is essen 
tially insoluble in Water effectively inhibits the development 
of experimentally induced uveitis. In human trials, cyclospo 
rine A has been shoWn to be effective in treating chronic 
uveitis, especially that associated With Behcet’s disease. 
Unfortunately, systemic therapy With cyclosporine A has 
serious draWbacks. Cyclosporine A used systemically has 
also been associated With a high incidence of renal toxicity, 
some cases of hepatotoxicity, hypertension, and an increased 
incidence of opportunistic infections. The systemic side 
effects of cyclosporine A are so severe and so common that 
its use to treat life-threatening or in some cases severe 
sight-threatening disease is not recommended. The systemic 
toxicity is such that the National Eye Institute has recom 
mended that, for uveitis in?icting one eye, cyclosporine 
should not be administered. Finally, a systemic application 
of cyclosporine A is limited by its prohibitive cost. Also, it 
should be noted that because of poor ocular availability, 
topical delivery does not result in the obtention of therapeu 
tic levels of the drug in the back of the eye. 
Accordingly, there exists a strong need for the elimination 
of the undesirable physiological and economic problems 
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associated With cyclosporine A treatment of uveitis, While 
maintaining the advantageous therapeutic properties of this 
treatment. 
The systemic toxicity of cyclosporine A may be mini 
miZed by delivering the drug locally. Although direct intra 
vitreal injection prevents experimental autoimmune uveitis 
(EAU), repeated injection is not a practical mode of admin 
istration. 
Due to the risks that certain drugs impose, researchers 
have developed systems for administering such drugs to aid 
in the treatment of ailments and diseases. The systems have 
been designed largely to reduce and to control the release 
rate of incorporated drugs. HoWever, these systems fail to 
achieve the surprising and unexpected results obtained by 
the present invention. 
For example, US. Pat. No. 5,091,185 to Castillo et al. 
relates to implantable pellets for veterinary use comprising 
a bioactive material such as somatotropin coated With a 
polyvinyl alcohol polymer to prolong the release of the 
bioactive material after implantation. Parenteral administra 
tion of the coated pellet is by subcutaneous implantation and 
may be accomplished surgically or by injecting small pellets 
through a needle. HoWever, the Castillo patent does not 
teach that the polyvinyl alcohol polymer should be heated to 
temperatures greater than about 100° C. to induce changes 
in the crystal structure of the polymer to render it nonerod 
ible. Somatotropins are heat sensitive and rapidly decom 
pose on heating above 100° C. so such heating Would be 
impractical for the systems described in the Castillo patent. 
U.S. Pat No. 4,300,557 to Refojo et al. relates to an 
improved process for dispensing a lipid-soluble, labile drug 
by diffusion from an implantable silicon capsule to a site 
Within an animal body being treated With the drug, Wherein 
the silicon capsule is provided With a tube sealed at its distal 
end and through the interior Wall of Which is cut a longitu 
dinal slit of 1 to 1.5 mm for ?lling the capsule folloWing 
implantation. The capsule is surgically implanted near the 
site being treated so that the tube is accessible for ?lling 
Without further surgical procedures. In another aspect of the 
invention, a drug is dispensed at a constant rate through an 
expandable, silicon microballoon implanted periocularly to 
an intraocular site Within an animal body. 
U.S. Pat No. 4,649,047 to KasWan relates to a method for 
the treatment of, for example, uveitis occurring throughout 
the globe of the eye, by topical administration of cyclospo 
rine to the eye. 
U.S. Pat No. 4,923,699 to Kaufman discloses an eye 
treatment system Wherein three dimensional particles of 
bioerodible material of a speci?c siZe Which are suspended 
in a liquid carrier or ointment carrier having a pH acceptable 
to the eye are delivered topically to the eye. Various agents 
may be added to increase viscosity, promote suspension 
and/or improve ocular compatibility. 
U.S. Pat No. 3,832,252 to Higuchi et al. relates to a drug 
delivery device comprising an inner solid matrix With solid 
particles of drug dispersed therethrough. Any solid material 
chemically compatible With the drug and permeable to 
passage of the drug by diffusion can be employed. 
U.S. Pat No. 4,309,996 to TheeuWes relates to a system 
comprising a microporous diffuser for delivering a bene?cial 
agent to a ?uid environment of use at a Zero order rate for 
an increased length of time at that rate. The system consists 
essentially of a microporous Wall, or a part microporous part 
semi-permeable Wall, surrounding a compartment having a 
space containing the agent separated by a partition from a 
space containing an expandable entity. 
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US. Pat No. 4,309,776 to Berguer relates to an intravas 
cular implantation device having a chamber for containing 
transplanted cells that is implanted in a Wall of a blood 
vessel or to be implanted betWeen an artery and a vein in a 
Wall of each for the purpose of introducing hormonal 
components into the bloodstream of a human being. It is 
disclosed that the material of Which the chamber-forming 
device is made must be tolerated in a blood vessel Without 
causing thrombosis and should permit the choice of various 
degrees of porosity. 
US. Pat No. 4,973,304 to Graham et al. relates to devices 
Which have use in medical or veterinary application as 
implants or as inserts. The devices can be implanted surgi 
cally into the body or introduced into a body cavity of a 
human patient or an animal such that the active substance 
diffuses out of the device through hydrogel WindoWs into the 
surrounding body region. The device may be in the form of 
a tube of Water-permeable material having at least one port 
in the tube Wall. 
The above described systems and devices are intended to 
provide sustained release of drugs effective in treating 
patients at a desired local or systemic level for obtaining 
certain physiological or pharmacological effects. HoWever, 
there are many disadvantages associated With their use. The 
need for a better release system is especially signi?cant in 
the treatment of uveitis. Thus, there remains a long-felt need 
in the art for an improved device for providing sustained 
release of a drug to a patient to obtain a desired local or 
systemic physiological or pharmacological effect. 
DISCLOSURE OF THE INVENTION 
Therefore, it is an object of this invention to provide a 
device suitable for the controlled and sustained release of a 
composition effective in obtaining a desired local or sys 
temic physiological or pharmacological effect and Which, 
once implanted, gives a continuous release to an affected 
area Without requiring additional invasions into the region. 
Moreover, the present invention is designed to hold the loW 
solubility agent in the correct anatomic location and to 
prevent disintegration of the inner core. By maintaining 
surface area, the present invention reduces ?uctuations in 
release characteristics. In one embodiment, ?uctuations 
caused by changes in the composition of the bathing ?uid are 
also eliminated. 
In one embodiment, the device includes an inner core 
comprising an effective amount of a loW solubility agent, 
and a non-erodible polymer coating layer, the polymer layer 
being permeable to the loW solubility agent, Wherein the 
polymer coating layer partially or completely covers the 
inner core. 
Another object of the present invention is to provide a 
method for treating a mammal, e.g., a human, to obtain a 
desired local or systemic physiological or pharmacological 
effect. The method includes securing the sustained release 
drug delivery device at an area Where release of the agent is 
desired and alloWing the agent to pass through the polymer 
coating layer to the desired area of treatment. 
A further object of the invention is to provide an ocular 
device suitable for direct implantation into the eye. Such 
devices of the present invention are surprisingly found to 
provide sustained release controlled release of various com 
positions to treat the eye Without risk of detrimental side 
effects. 
An additional object of the present invention is to provide 
an ocular delivery system that could be applied to an 
intraocular lens to prevent in?ammation or posterior capsu 
lar opaci?cation. 
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Another object of the present invention is to provide a 
means of achieving and maintaining therapeutic levels of 
trans retinoic acid, cis retinoic acid and other related retinoid 
compounds in the eye. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
carrying out the invention. As is readily recogniZed the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1 is an enlarged vieW of an embodiment of the 
sustained release drug delivery device shoWing inner drug 
core and permeable polymer coating. 
FIG. 2 is an enlarged vieW of an embodiment of the 
sustained release drug delivery device shoWing inner drug 
core, permeable polymer coating of the present invention 
and an extension of the polymer coating layer as a means for 
attachment. 
FIG. 3 is an enlarged vieW of an embodiment of the 
sustained release drug delivery device shoWing inner drug 
core, permeable polymer coating layer and an extension of 
the polymer coating layer containing a support ring as a 
means for attachment Wherein the support ring alloWs 
enough space for a suture to be passed betWeen the drug core 
and the support ring. 
FIG. 4 is an enlarged vieW of an embodiment of the 
sustained release drug delivery device showing inner drug 
core, permeable polymer coating layer and an extension of 
the polymer coating layer containing a support ring as a 
means for attachment Wherein the support ring forms a loop 
through Which a suture can be passed. 
FIG. 5 is an enlarged vieW of an embodiment of the 
sustained release drug delivery device shoWing inner drug 
core, permeable polymer coating layer and an extension of 
the polymer coating layer containing a backing material as 
a means for attachment. 
FIG. 6 is an enlarged vieW of an embodiment of the 
sustained release drug delivery device shoWing inner drug 
core, permeable polymer coating layer and an extension of 
the polymer coating layer containing a backing material as 
a means for attachment. 
FIG. 7 shoWs a graph indicating that 0.5% albumin 
uncoated retinoic acid pellets release signi?cantly faster than 
retinoic acid in the devices according to the invention. 
FIG. 8 shoWs clearance of cyclosporine from the vitreous 
folloWing a 1 pg injection. 
FIG. 9 shoWs clearance of cyclosporine from the vitreous 
folloWing a 10 pg injection. 
FIG. 10 shoWs tissue levels of cyclosporine folloWing a 
10 pg injection into the midvitreous. 
FIG. 11 shoWs vitreous concentration of cyclosporine 
folloWing device implantation measured over 6 months. 
FIG. 12 shoWs tissue levels of cyclosporine folloWing 
device implantation measured over 6 months. Note rela 
tively high levels in the lens. Bars represent SEM. 
FIG. 13 shoWs ERG data demonstrating decrease in 
scotopic b-Wave amplitude. Data represented as the ratio 
b-Wave amplitude in drug eye to b-Wave amplitude in 
control eye. Bars represent SEM. 
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FIG. 14 shows ERG data demonstrating recovery of ERG 
following removal of the sustained release device containing 
cyclosporine. Data represented as the ratio b-Wave ampli 
tude in drug eye to b-Wave amplitude in control eye. Bars 
represent SEM. 
FIG. 15 shoWs ERG data in the monkey over 6 months 
demonstrates no evidence of retinal toxicity. Bars represent 
SEM. 
DESCRIPTION OF THE INVENTION 
The present inventors have surprisingly and unexpectedly 
discovered a device that is suitable for the controlled and 
sustained release of an agent effective in obtaining a desired 
local or systemic physiological or pharmacological effect. 
The device includes an inner core comprising an effective 
amount of a loW solubility agent, and a non-bioerodible 
polymer coating layer, the polymer layer permeable to the 
loW solubility agent, Wherein the polymer coating layer 
covers the inner core. 
Once implanted, the device gives a continuous supply of 
the agent to internal regions of the body Without requiring 
additional invasive penetrations into these regions. Instead, 
the device remains in the body and serves as a continuous 
source of the agent to the affected area. In another 
embodiment, the device further comprises a means for 
attachment, such as an extension of the non-erodible poly 
mer coating layer, a backing member, or a support ring. In 
a preferred embodiment, the device is suitable for direct 
implantation into the vitreous of the eye. 
The device according to the present invention permits 
prolonged constant release of loW solubility agents over a 
speci?c period of months (e.g., 3 months, 6 months) or years 
(e.g., 1 year, 5 years, 10 years, 20 years) until the agent is 
substantially used up. 
Suitable loW solubility agents useful in the present inven 
tion include immune response modi?ers such as cyclospo 
rine A and FK 506, corticosteroids such as dexamethasone 
and triamcinolone acetonide, angiostatic steroids such as 
trihydroxy steroid, anti-parasitic agents such as atovaquone, 
anti-glaucoma agents such as ethacrynic acid, antibiotics 
including cipro?oxacin, differentiation modulators such as 
retinoids (e.g., trans-retinoic acid, cis-retinoic acid and 
analogues), anti-viral agents including high molecular 
Weight loW (10-mers) loW solubility anti-sense compounds, 
anti-cancer agents such as BCNU, nonsteroidal anti 
in?ammatory agents such as indomethacin and ?urbiprofen, 
codrugs including loW solubility codrugs of salts or conju 
gates of synergistic pharmacological agents such as suramin/ 
amiloride or 5-FU/T HS, and combinations thereof. The 
compounds that may be employed in the practice of the 
present invention should be in loW solubility form. Refer 
ence may be made to any standard pharmaceutical textbook 
for the procedures to obtain a loW solubility form of a drug. 
By “loW solubility”, it is meant a solubility less than about 
10 pg of compound per 1 ml (of Water at a temperature of 
25° C. as measured by procedures set forth in the 1995 
USP). This includes compounds Which are slightly soluble 
(about 0.01 pg/ml-about 0.001 pig/ml), very slightly 
insoluble (about 0.001 pg/ml-about 0.0001 pig/ml) and prac 
tically insoluble or insoluble compounds (less than about 
0.0001 pig/ml). 
Examples of compounds having a loW solubility include, 
but are not limited to, erythromycin, levodopa, 
methotrexate, chloroquin, cholothiaZide, ?uocinolone 
acetonide, rifampin, acetomoliZide, theophyllyne, and tetra 
cane. 
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Material that may be suitable for fabricating the polymer 
coating layer of the device include naturally occurring or 
synthetic materials that are biologically compatible With 
bodily ?uids and eye tissues, and essentially insoluble in 
bodily ?uids With Which the material Will come in contact. 
In addition, the suitable materials essentially prevent inter 
action betWeen the loW solubility agent in the inner core of 
the device and proteinaceous components in the bodily ?uid. 
The use of rapidly dissolving materials or materials highly 
soluble in eye ?uids or Which permit interaction betWeen the 
loW solubility agent in the inner core and proteinaceous 
components in the bodily ?uids are to be avoided since 
dissolution of the Wall or interaction With the proteinaceous 
components Would affect the constancy of drug release, as 
Well as the capability of the device to remain in place for a 
prolonged period. Suitable polymers useful in the present 
invention include polyvinyl alcohol, ethylene vinyl acetate, 
silicone, polylactic acid, nylon, polypropylene, 
polycarbonate, cellulose, cellulose acetate, polyglycolic 
acid, polylactic glycolic acid, cellulose esters or polyether 
sulfone. The polymer coating layer is non-bioerodible and is 
permeable to the loW solubility agent Without being release 
rate limiting. 
The cyclosporines Which are useful in the practice of the 
present invention may be both natural or synthetic cyclospo 
rines. For example, cyclosporine A may be used in the 
practice of the present invention. Other forms of cyclospo 
rines (e.g., isomers) may also be used. Mixtures of at least 
tWo different cyclosporines may be used. The only require 
ment is that the cyclosporine possess the required activity 
vis-a-vis uveitis and is of extremely loW solubility. 
This device enables a large variety of drugs and other 
agents to be delivered into any internal region of the body, 
preferably the eye. Cyclosporine A in loW solubility form is 
a preferred drug used in the delivery device. 
The non-bioerodible polymer coating layer of the present 
invention may completely or partially cover the inner core. 
In this regard, any portion of the surface area of the inner 
core up to and including 100% may be coated With the 
polymer coating layer as long as the pellet is protected 
against disintegration, prevented from being physically dis 
placed from its required site, and as long as the polymer 
coating layer does not adversely retard the release rate. 
The method for treating a mammal to obtain a desired 
local or systemic physiological or pharmacological effect 
includes surgically implanting the sustained release drug 
delivery device of the present invention into the mammal 
and alloWing agent to pass through the device to come in 
direct contact With the mammal. 
The drug delivery device of the present invention may be 
administered to a mammal via any route of administration 
knoWn in the art. Such routes of administration include 
intraocular, intraarticular, subcutaneous, vaginal, 
intramuscular, intraperitoneal, intranasal, dermal, and the 
like. In addition, one or more of the devices may be 
administered at one time or more than one agent may be 
included in the inner core. 
The drug delivery device of the present invention is 
particularly suitable for direct surgical implantation into the 
eye. 
The entire structure is made of material Which is com 
patible With the human tissue With Which it comes in contact. 
In a preferred embodiment the material of the device is 
polyvinyl alcohol. If a backing member is present in a 
preferred embodiment, the backing member may be com 
posed of any material tolerated by the human body, prefer 
ably ethylene vinyl acetate, Te?on, silicone, silastic and 
nylon. 
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These methods of administration and technique for their 
preparation are Well known by those of ordinary skill in the 
art. Techniques for their preparation are set forth in Rem 
ington’s Pharmaceutical Sciences. 
The drug delivery device may be administered for a 
sufficient period of time and under conditions to alloW 
treatment of the disease state of concern. 
For localiZed drug delivery, the device may be surgically 
implanted at or near the site of action. This is the case for 
devices of the present invention used in treating ocular 
conditions, primary tumors, rheumatic and arthritic 
conditions, and chronic pain. The device may be used to 
control the rate of drug delivery to any internal region of the 
body. 
For systemic relief, the devices may be implanted 
subcutaneously, intramuscularly or intraperitoneally. This is 
the case When devices are to give sustained systemic levels. 
The folloWing examples are merely illustrative of the 
present invention and they should not be considered as 
limiting the scope of the invention in any Way, as these 
examples and other equivalents Will become more apparent 
to those skilled in the art in light of the present disclosure. 
EXAMPLE 1 
Adevice according to the present invention Was prepared. 
This device Was composed of a 5 mg core of cyclosporine 
A(obtained from the National Eye Institute as a gift) coated 
in polyvinyl alcohol (PVA) (obtained from Polysciences, 
Inc.) and heated at 110° C. for 10 minutes. In design it 
resembled FIG. 2. The device Was implanted into the vitre 
ous of 3 monkeys and appeared safe. Another monkey 
received an identical pellet and after 6 months Was sacri?ced 
and a sample of vitreous obtained. Analysis shoWed the 
concentration of cyclosporine to be 60 ng/ml. This indicates 
that the system can be used to maintain therapeutic levels of 
drug (in this case cyclosporine) in the eye for prolonged 
periods. Due to the “soft” nature of PVA When heated to 
110° C. an improved device Would contain a support ring or 
backing (FIG. 4 or 6). 
EXAMPLE 2 
Adevice according to the present invention Was prepared. 
This device Was composed of a 3 mm, 12 mg disc of retinoic 
acid encased in silicone. It resembles FIG. 3 in appearance. 
The implant Was prepared by preparing a thin ?lm of 
silicone. A 2.5 mm hole Was then cut through the ?lm and 
the retinoic acid pellet ?xed directly over the hole using 
silicone. A loop of Prolene suture Was placed over the pellet 
and ?xed onto the surface of the ?lm so that a “gap” of over 
1 mm Was present betWeen the pellet and the suture all the 
Way around. The entire assembly Was then coated again in 
silicone. These pellets Were sutured onto the surface of the 
sclera in 3 rabbits and the ERGs taken every Week for 5 
Weeks. There Was no evidence of toxicity. 
EXAMPLE 3 
Pellets of retinoic acid Were prepared by compressing 2 
mg of the compound in a 1.5 mm Parr Instruments Press. 
Some pellets Were then coated in PVA and heated to 120° C. 
and trimmed leaving a suture tab attached as shoWn in FIG. 
2 While other pellets Were not coated. Uncoated pellets and 
devices Were immersed in 1 ml of phosphate buffer (pH 7.4) 
containing 0.5% albumin at 37° C. After 24 hours the buffer 
Was replaced With fresh and the amount of drug released 
calculated by HPLC. After approximately 25 days buffer 
containing 1.0% albumin Was added and the experiment 
continued. 
10 
15 
20 
25 
40 
45 
55 
60 
65 
8 
As can be seen from the graph depicted in FIG. 7, in 0.5% 
albumin uncoated retinoic acid pellets release signi?cantly 
faster than retinoic acid in the devices. This is due in part to 
the coating preventing small particles of poWder from ?ak 
ing from the surface and increasing the surface area. Increas 
ing the albumin concentration greatly increases the release 
rate of retinoic acid from the pellets but has minimal effect 
on release from the device. 
This stabiliZation is important in many diseases, espe 
cially ophthalmic diseases. In some eye diseases the albumin 
concentration of the vitreous and aqueous can increase by a 
factor of 40. Without the release stabiliZing properties of the 
device this Would cause a huge increase in release rate With 
unforetold consequences. 
EXAMPLE 4 
All animal procedures Were performed using NeW 
Zealand albino rabbits of either sex Weighing approximately 
2 kg and adhered to the guidelines set forth by the Asso 
ciation for Research in Vision and Ophthalmology for ani 
mal use in research. 
TWenty four animals (Group 1) Were used. Cyclosporine 
Was mixed into stock solutions of 50:50 ethanol:Water at a 
concentration of 1 pg/20 pl and 10 pg/20 pl. 3H-labeled 
cyclosporine (1 pCi/20 pl) Was also added to the stock 
solution. Animals Were anesthetiZed With ketamine (60 mg) 
and xylaZine (20 mg) and the pupils Were dilated With one 
drop of phenylephrine hydrochloride (2.5%) and tropicam 
ide (1%). An intravitreal injection of cyclosporine Was then 
given through the superior rectus muscle approximately 5 
mm posterior to the limbus using a 30 gauge needle. TWelve 
animals received a dose of 1 pg(20 pl) and 12 animals 
received a dose of 10 pg(20 pl). The injection Was given into 
the midvitreous cavity and care Was taken to avoid the lens. 
For the 1 pg group, 3 animals Were sacri?ced at 0.5, 3, 6 and 
24 hours. For the 10 pg group, 3 animals Were sacri?ced at 
0.5, 6, 24 and 48 hours. The eyes Were enucleated and then 
immediately froZen at —70° C. Tissues Were prepared for 
assay as described beloW. Intravitreal half-life and volume of 
distribution Were determined from regression analysis of a in 
concentration versus time plot. 
FolloWing a 1 pg injection the regression equation of in 
concentration versus time for vitreous levels Was y=1.17— 
0.15x (R2=0.99)Wh1Ch equates to a half-life of 4.2 hours and 
distribution volume of 3.2 ml (FIG. 8). FolloWing the 10 pg 
injection the regression equation for vitreous levels Was 
y=1.75—0.058x (R2=0.99) Which equates to a half-life of 
10.8 hours and a volume of distribution of 1.7 ml (FIG. 9). 
Analysis of tissue samples (FIG. 10) demonstrated relatively 
high lens levels. The drug content in the lens remained high 
throughout the study period. Thirty minutes folloWing the 1 
pg injection the amount of cyclosporine in the vitreous Was 
0.39 pg While the total drug present in all of the remaining 
ocular tissue samples Was 0.27 pg. Thus the ratio of total 
tissue cyclosporine to vitreous cyclosporine Was 0.69. Thirty 
minutes after the 10 pg injection there Was 7 pg of cyclospo 
rine in the vitreous and 0.75 pg of cyclosporine in the tissues 
Which equates to a total tissue cyclosporine to vitreous 
cyclosporine ratio of 0.11. 
EXAMPLE 5 
Eighteen animals (Group 2) Were used. Devices consisted 
of a core of 5 mg of cyclosporine Which Wa labeled With 13.6 
pCi 3H-cyclosporine. 
The core, Which measured 2.5 mm in diameter, Was 
coated With several layers of polyvinyl alcohol and then heat 




